作者
Vicky Mai, Charles-Antoine Guay, Laurie Perreault, Sébastien Bonnet, Laurent Bertoletti, Yves Lacasse, Sabine Jardel, Jean-Christophe Lega, Steeve Provencher
发表日期
2019/6/1
来源
Chest
卷号
155
期号
6
页码范围
1199-1216
出版商
Elsevier
简介
Background
The efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) during extended anticoagulation for a VTE remains largely unknown, especially in terms of potential survival benefit. The goal of this study was to assess the effects of VKAs and DOACs on overall mortality and VTE-related mortality, as well as VTE recurrence and safety.
Methods
PubMed, EMBASE, and the Cochrane Library were searched from January 1990 through September 2018 for randomized controlled trials evaluating the effect of extended anticoagulants as secondary prevention for VTE compared with placebo. The primary outcome was the specific effects of standard-intensity VKAs and DOACs on overall mortality.
Results
Sixteen studies (12,458 patients) were included. DOACs were associated with a reduction in overall (risk ratio [RR], 0.48; 95% CI, 0.27-0.86; P = .01) and VTE-related (RR, 0.36; 95 …
学术搜索中的文章
V Mai, CA Guay, L Perreault, S Bonnet, L Bertoletti… - Chest, 2019